MedTech (device segment)
Q2 2026 growth led by surgery (wound closure and biosurgery), electrophysiology, Shockwave and vision.
The numbers
What it is
Devices across surgery, orthopaedics, cardiovascular (electrophysiology and Shockwave lithotripsy) and vision (contact lenses). It is the second segment and the base for the OTTAVA surgical robot.
Why it matters to the stock. About 36% of fiscal 2025 sales. Its growth rate is lower than Innovative Medicine, so investors watch whether MedTech can hold its share of total growth.
News
J&J Q1 2026 sales rise 9.9% to $24.1 billion and 2026 sales guidance is raised to $100.3-101.3 billion
Johnson & Johnson reported first-quarter 2026 sales of $24.1 billion, up 9.9% reported and 6.4% operationally, with adjusted EPS of $2.70 against $2.77 a year earlier.
J&J closes 2025 with $24.6 billion fourth quarter and guides 2026 sales to $100.0-101.0 billion
Johnson & Johnson reported fourth-quarter 2025 sales of $24.6 billion, up 9.1% reported and 7.1% operationally, with adjusted EPS of $2.46.